JP Morgan Call 135 R66 17.01.2025/ DE000JL2EUS3 /
30/07/2024 10:54:29 | Chg.-0.21 | Bid18:41:57 | Ask18:41:57 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.72EUR | -10.88% | 2.26 Bid Size: 50,000 |
2.28 Ask Size: 50,000 |
PHILLIPS 66 D... | 135.00 - | 17/01/2025 | Call |
GlobeNewswire
01/07
Phillips Edison & Company Announces Appointment of Devin Murphy to Board of Directors
GlobeNewswire
27/06
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Inte...
GlobeNewswire
25/06
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technolog...
GlobeNewswire
20/06
The International Food Information Council (IFIC) Releases Annual Food & Health Survey Revealing Ris...
GlobeNewswire
17/06
Phillips Edison & Company Inc. Invites You to Join Its Second Quarter 2024 Earnings Conference Call
GlobeNewswire
17/06
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
12/06
Greystone Closes $22.9 Million in Total Debt Placement and Preferred Equity Financing for Fort Worth...
GlobeNewswire
05/06
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
29/05
Phillips Edison & Company to Present at Nareit REITweek 2024 Investor Conference
GlobeNewswire
22/05
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
GlobeNewswire
20/05
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease We...
GlobeNewswire
16/05
Optimal Daily Dairy Consumption Remains Elusive Despite Well-Established Health Benefits
GlobeNewswire
16/05
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)